Last reviewed · How we verify
Non-Hodgkin lymphoma — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | Pfizer Inc. | Anthracycline topoisomerase inhibitor | DNA topoisomerase II, nucleotide bases |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer Inc. · 1 drug in Non-Hodgkin lymphoma
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Non-Hodgkin lymphoma:
- Non-Hodgkin lymphoma treatment updates — RSS
- Non-Hodgkin lymphoma treatment updates — Atom
- Non-Hodgkin lymphoma treatment updates — JSON
Cite this brief
Drug Landscape (2026). Non-Hodgkin lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/non-hodgkin-lymphoma. Accessed 2026-06-10.
Related
- Non-Hodgkin lymphoma full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing